Prescrire Int. 2011 May;20(116):126.
Prospective follow-up for a median of 35 months of a French cohort of 19 486 patients with inflammatory bowel disease showed a nearly 4-fold increase in the risk of lymphoma in patients exposed to azathioprine or mercaptopurine (relative risk 3.75; 95% confidence interval 1.59 to 8.85). This risk should be taken into account when weighing the likely benefits of these drugs in treatment of patients with severe chronic inflammatory bowel disease no longer responding to first-line treatment.
对法国一个由19486例炎症性肠病患者组成的队列进行了为期35个月的中位随访，结果显示，使用硫唑嘌呤或巯嘌呤的患者患淋巴瘤的风险增加了近4倍（相对风险3.75；95%置信区间1.59至8.85）。在权衡这些药物对不再对一线治疗有反应的重度慢性炎症性肠病患者治疗可能带来的益处时，应考虑到这种风险。
